Cell cycle control and apoptosis: molecular mechanisms in tumour pathology

Overview

Disruption of cell cycle control and apoptosis is a near-universal feature of human malignancy. The molecular machinery involved, the cyclin-CDK engine, RB1 and TP53 checkpoint systems, the BCL-2 family apoptotic rheostat, the caspase execution cascade, and the MDM2 regulatory axis, directly determines tumour grade and behaviour and underlies most clinically relevant drug resistance mechanisms. These concepts are foundational to adrenal neoplasm pathology and the RCPA Fellowship examination.

The CDK/Cyclin Engine

Core Complexes

CDKs are constitutively expressed serine/threonine kinases that are catalytically inactive alone. Binding to transiently synthesised cyclins confers oscillatory kinase activity. More than 15 cyclins have been identified; cyclins D, E, A, and B appear sequentially and bind one or more CDKs.

The restriction point in $G_1$ is the critical commitment gate beyond which cells complete division regardless of mitogenic signals.

CDK Inhibitors (CDKIs)

Two structurally and functionally distinct families exert negative control:

Loss of CDKI function, most commonly homozygous deletion or promoter hypermethylation of CDKN2A, is among the most frequent molecular events across solid tumours. Defective CDKIs permit division of cells with damaged DNA, generating mutated daughter cells at risk of malignant transformation.

RB1: Governor of the G₁/S Checkpoint

Mechanism

RB1 encodes a pocket protein that, in its hypophosphorylated (active) state, binds and sequesters E2F transcription factors. The RB-E2F complex recruits histone deacetylases and histone methyltransferases to repress transcription of S-phase genes. Sequential phosphorylation by Cyclin D-CDK4/6 and then Cyclin E-CDK2 hyperphosphorylates RB, releasing E2F to activate S-phase gene transcription. Once past the restriction point, cells are committed to completing mitosis.

Mechanisms of RB Inactivation in Cancer

The G₁/S checkpoint is defective in most cancers through mutation of one of four regulatory nodes:

Downstream consequence: Aberrant E2F liberation drives constitutive S-phase transcription. Beyond dysregulated proliferation, this checkpoint failure impairs DNA damage surveillance, fostering genomic instability and a mutator phenotype.

TP53: Guardian of the Genome

Activation

TP53 (17p13.1) encodes a tetrameric transcription factor, the central cellular stress monitor. Under basal conditions, MDM2 continuously ubiquitinates p53, targeting it for proteasomal degradation. Stress disrupts this interaction, stabilising p53.

Two principal activation checkpoints:

1. DNA damage checkpoint: ATM/ATR kinases → Chk1/Chk2 → phosphorylation of both p53 and MDM2 → dissociation → p53 accumulation
2. Oncogene checkpoint: Oncoproteins (e.g. MYC, RAS) → aberrant G₁/S signalling → p14/ARF upregulation → MDM2 sequestration → p53 stabilisation

Additional inducers: hypoxia, ribonucleotide depletion, telomere shortening.

p53 Effector Programmes

MDM2 Regulation

MDM2 operates via classic negative feedback:

• p53 transcriptionally activates MDM2
• MDM2 binds the p53 N-terminal transactivation domain → inhibits transcriptional activity and targets p53 for ubiquitin-mediated proteasomal degradation
• ATM-mediated phosphorylation of both proteins under genotoxic stress disrupts this interaction

p14/ARF (encoded by an alternative reading frame of CDKN2A, distinct from p16/INK4a) binds and sequesters MDM2, preventing p53 degradation. This is the principal mechanism by which oncogenic signalling engages the p53 pathway, the oncogene checkpoint.

Cancer-associated disruption of the MDM2-p53 axis:

BCL-2 Family: The Apoptotic Rheostat

Intrinsic (Mitochondrial) Pathway

The intrinsic pathway is governed by BCL-2 family proteins controlling mitochondrial outer membrane permeabilisation (MOMP). Once MOMP occurs, cytochrome c is released, binds APAF-1 to form the apoptosome, and activates caspase-9.

The balance between these subgroups determines cell fate. p53 upregulates PUMA and NOXA, tipping balance toward apoptosis. Loss of p53 function specifically prevents PUMA upregulation in response to DNA damage, enabling survival of cells that would otherwise undergo apoptosis.

IAPs (Inhibitor of Apoptosis Proteins) provide an additional brake by blocking active caspase-9; SMAC/DIABLO, co-released from mitochondria with cytochrome c, neutralises IAPs.

Prototypic example: Follicular lymphoma, $t(14;18)(q32;q21)$ fuses BCL2 to the immunoglobulin heavy-chain locus, driving constitutive BCL-2 overexpression. Indolent behaviour reflects reduced cell death rather than explosive proliferation.

Extrinsic (Death Receptor) Pathway

Ligand binding to FAS/CD95 or TNFR1 → receptor clustering → FADD recruitment → caspase-8 activation (initiator). Caspase-8 directly activates executioner caspases or cleaves BID to truncated BID (tBID), which amplifies the signal via the intrinsic pathway (cross-talk). FLIP (competes with caspase-8 for FADD) is an intracellular inhibitor expressed by normal but not tumour cells that confers selectivity to TRAIL-based approaches.

Caspase Cascade: The Execution Phase

Caspases (cysteine-aspartate proteases) exist as inactive zymogens activated by proteolytic cleavage:

$$\text{Procaspase} \xrightarrow{\text{proteolytic cleavage}} \text{Active caspase}$$

Executioner caspases cleave structural proteins (lamins, cytoskeletal components), DNA repair enzymes, and CAD/ICAD (releasing the DNase responsible for internucleosomal DNA laddering). Morphological hallmarks: nuclear condensation (pyknosis), nuclear fragmentation (karyorrhexis), cell shrinkage, intact membrane blebbing into apoptotic bodies, no inflammatory response.

Cancer cells evade apoptosis via:

• Loss of TP53 function → failure to upregulate PUMA/BAX
• Overexpression of anti-apoptotic BCL-2 family members (BCL-2, MCL-1)
• Epigenetic silencing of APAF-1 or caspase-8
• Overexpression of IAPs

Implications for Tumour Grade and Drug Resistance

Tumour Grade

Higher-grade tumours characteristically show:

• Elevated Ki-67 proliferative index (dysregulated CDK/cyclin activity):

$$\text{Ki-67 index} = \frac{\text{Ki-67 positive nuclei}}{\text{total nuclei counted}} \times 100\%$$

• TP53 loss (genomic instability, pleomorphism, high mitotic rate)
• RB1 loss (unrestrained S-phase entry)
• Reduced apoptosis (BCL-2 overexpression, caspase pathway silencing)

In adrenocortical carcinoma, the Weiss scoring system assigns points for high mitotic rate (>5/50 HPF) and atypical mitoses, both direct reflections of deranged CDK/cyclin and checkpoint function. High-grade ACC frequently demonstrates TP53 mutation and CDKN2A loss.

Drug Resistance

Therapeutic Exploitation

Diagnostic Pitfalls

• p53 IHC interpretation: Both complete absence of staining (nonsense/frameshift → unstable protein) and diffuse strong overexpression (missense → stabilised non-functional protein) indicate TP53 loss-of-function. Wild-type p53 produces heterogeneous low-level staining. Diffuse strong positivity must not be interpreted as functional p53.
• BCL-2 in follicular lymphoma vs reactive germinal centres: Reactive germinal-centre B-cells are BCL-2 negative; follicular lymphoma cells are BCL-2 positive, a key diagnostic distinction.
• MDM2 amplification without TP53 mutation: WD/DD liposarcoma is the paradigmatic example, high-level MDM2 amplification at 12q13-15 effectively silences wild-type p53; MDM2 IHC and FISH are key ancillary tests.
• CDKN2A locus duality: A single locus encodes both p16/INK4a (CDK4/6 inhibitor → RB pathway) and p14/ARF (MDM2 inhibitor → p53 pathway) via alternative reading frames; deletion simultaneously disables both tumour suppressor axes.
• Ki-67 quantification: Intratumoral heterogeneity and fixation artefacts affect results; standardised hot-spot methodology per RCPA/WHO guidelines is required for reproducible grading.

Sources

• RCPA manual & guidelines (Royal College of Pathologists of Australasia)
• WHO Classification of Tumours (open abstracts)
• CAP Cancer Protocols (College of American Pathologists)